Skip to main content
Journal cover image

Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients (pts) with Brincidofovir: Final 36 Week Results from the Advise Trial

Publication ,  Conference
Prasad, VK; Papanicolaou, GA; Maron, GM; Vainorius, E; Brundage, TM; Chittick, G; Nichols, G; Grimley, MS
Published in: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2017

Duke Scholars

Published In

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

EISSN

1523-6536

ISSN

1083-8791

Publication Date

2017

Volume

23

Issue

3

Start / End Page

S52 / S53

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Prasad, V. K., Papanicolaou, G. A., Maron, G. M., Vainorius, E., Brundage, T. M., Chittick, G., … Grimley, M. S. (2017). Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients (pts) with Brincidofovir: Final 36 Week Results from the Advise Trial. In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (Vol. 23, pp. S52–S53).
Prasad, Vinod K., Genovefa A. Papanicolaou, Gabriela M. Maron, Enrikas Vainorius, Thomas M. Brundage, Greg Chittick, Garrett Nichols, and Michael S. Grimley. “Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients (pts) with Brincidofovir: Final 36 Week Results from the Advise Trial.” In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23:S52–53, 2017.
Prasad VK, Papanicolaou GA, Maron GM, Vainorius E, Brundage TM, Chittick G, et al. Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients (pts) with Brincidofovir: Final 36 Week Results from the Advise Trial. In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2017. p. S52–3.
Prasad VK, Papanicolaou GA, Maron GM, Vainorius E, Brundage TM, Chittick G, Nichols G, Grimley MS. Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients (pts) with Brincidofovir: Final 36 Week Results from the Advise Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2017. p. S52–S53.
Journal cover image

Published In

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

EISSN

1523-6536

ISSN

1083-8791

Publication Date

2017

Volume

23

Issue

3

Start / End Page

S52 / S53

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences